Analysts Set Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) PT at $6.50

Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTXGet Rating) have received a consensus recommendation of “Buy” from the six brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $6.50.

LCTX has been the subject of several research analyst reports. Maxim Group reiterated a “buy” rating and set a $5.00 target price on shares of Lineage Cell Therapeutics in a research note on Friday. Dawson James reaffirmed a “buy” rating and issued a $6.00 target price on shares of Lineage Cell Therapeutics in a report on Friday, March 11th. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Lineage Cell Therapeutics in a report on Friday, March 11th. TheStreet lowered shares of Lineage Cell Therapeutics from a “c-” rating to a “d+” rating in a report on Thursday, February 24th. Finally, Zacks Investment Research lowered shares of Lineage Cell Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, March 16th.

LCTX stock opened at $1.15 on Friday. Lineage Cell Therapeutics has a 52-week low of $1.10 and a 52-week high of $3.00.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTXGet Rating) last posted its earnings results on Thursday, March 10th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Lineage Cell Therapeutics had a negative return on equity of 27.43% and a negative net margin of 528.23%. The business had revenue of $1.20 million during the quarter, compared to the consensus estimate of $1.20 million. On average, equities research analysts expect that Lineage Cell Therapeutics will post -0.14 earnings per share for the current year.

In related news, Director Dipti Amin bought 35,000 shares of the company’s stock in a transaction on Monday, March 28th. The shares were purchased at an average cost of $1.63 per share, for a total transaction of $57,050.00. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have acquired a total of 53,650 shares of company stock worth $83,887 over the last 90 days. Corporate insiders own 26.20% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Goldman Sachs Group Inc. raised its stake in Lineage Cell Therapeutics by 29.2% in the first quarter. Goldman Sachs Group Inc. now owns 127,432 shares of the company’s stock valued at $196,000 after purchasing an additional 28,773 shares in the last quarter. State Street Corp raised its stake in Lineage Cell Therapeutics by 1.5% during the first quarter. State Street Corp now owns 2,105,107 shares of the company’s stock worth $3,242,000 after acquiring an additional 30,873 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Lineage Cell Therapeutics by 5.4% during the first quarter. Charles Schwab Investment Management Inc. now owns 332,406 shares of the company’s stock worth $512,000 after purchasing an additional 17,052 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Lineage Cell Therapeutics by 44.1% during the first quarter. JPMorgan Chase & Co. now owns 1,849,662 shares of the company’s stock worth $2,849,000 after purchasing an additional 566,385 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new stake in shares of Lineage Cell Therapeutics during the first quarter worth about $112,000. 45.12% of the stock is owned by institutional investors.

About Lineage Cell Therapeutics (Get Rating)

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.

Featured Articles

Receive News & Ratings for Lineage Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lineage Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.